Leiner Looks To Rule Claritin Equivalent Market With Summer Launches
This article was originally published in The Tan Sheet
Executive Summary
Leiner Health Products will seek to control the store brand loratadine market with late summer launches of equivalents to Schering-Plough's Claritin RediTabs and D-24
You may also be interested in...
Leiner Loratadine Success In 2004 Positions Firm For Further OTC Growth
Leiner views its OTC sales growth during its first fiscal quarter as representative of the way the company is reshaping its current business strategy to focus more on nonprescription drugs
Impax and Leiner
Hayward, Calif. -based drug delivery firm has signed a series of agreements with Leiner for supply and distribution of Claritin equivalents slated for late-summer launch, Impax announces July 12. Products include store brand versions of Reditabs and D-24 (1"The Tan Sheet" June 21, 2004, p. 5). The deal "enables IMPAX to further capitalize on our loratadine product franchise," according to CEO Barry Edwards...
Loratadine Private Labelers Gain On Branded Alternatives
Private label loratadine is making market share inroads against branded Claritin (Schering-Plough) and Alavert (Wyeth)